Researchers have found in a new study that Children with mucopolysaccharidosis (MPS) undergoing adenotonsillectomy (AT) ...

The patients have conditions such as Fabry disease, Gaucher disease or mucopolysaccharidosis — inherited disorders caused by ...

JCR Pharma introduces mucopolysaccharidosis type II disease awareness film featured in the Next Frontier series: Hyogo, Japan Friday, June 20, 2025, 18:00 Hrs [IST] JCR Pharmaceut ...

JCR announced the launch of a film featured in The Next Frontier, a series presented by BIO and produced by BBC StoryWorks ...

Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline ...

The mucopolysaccharidosis treatment market is an evolving and crucial segment within the rare disease pharmaceutical ...

DataM Intelligence | competitive Intelligence MPS I market evolution accelerates as gene therapies and BBB-penetrant ERTs emerge, challengi ...

DelveInsight’s, “Mucopolysaccharidosis Type I Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucopolysaccharidosis Type I pipeline ...

Morningstar brands and products Company Portfolio ...

Simpson, NASDAQ: RGNX) for RGX-121 (clemidsogene lanparvovec), a potential first-in-class, investigational gene therapy for the treatment of Mucopolysaccharidosis II (MPS II). The FDA granted ...